Meeting
2015 ASCO Annual Meeting
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.
Authors
Ian Chau
Royal Marsden, London & Surrey, United Kingdom
Ian Chau , Markus Peck-Radosavljevic , Christophe Borg , Peter Malfertheiner , Jean Francois Seitz , Joon Oh Park , Baek-Yeol Ryoo , Chia-Jui Yen , Masatoshi Kudo , Ronnie Tung-Ping Poon , Davide Pastorelli , Jean-Frédéric Blanc , Hyun Cheol Chung , Ari David Baron , Takuji Okusaka , Zhanglin Lin Cui , Allicia C. Girvan , Paolo Abada , Ling Yang , Andrew X. Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01140347
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4077)
DOI
10.1200/jco.2015.33.15_suppl.4077
Abstract #
4077
Poster Bd #
187
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2020 Gastrointestinal Cancers Symposium
Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.
First Author: Erica S. Tsang
Poster
2019 Gastrointestinal Cancers Symposium
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
First Author: Masatoshi Kudo